P-280Pembrolizumab versus physician-choice chemotherapy for previously treated patients with advanced/metastatic squamous or adenocarcinoma of the esophagus or Siewert I adenocarcinoma of the esophagogastric junction (EGJ): Randomized, phase 3 KEYNOTE-18